SummaryWe report the cloning and characterization of a novel 54‐kDa high‐mobility group (HMG)‐box protein as the ligand for the human pan‐B cell co‐receptor CD19 (CD19‐L), which interacts with the extracellular domain of CD19 in trans. CD19‐L is the first CD19‐specific recombinant human protein with potent anti‐leukaemic activity against B‐lineage acute lymphoblastic leukaemia (ALL), the most common form of childhood cancer and the second most common form of acute leukaemia in adults. Soluble recombinant CD19‐L protein exhibited exquisite specificity for the extracellular domain of CD19 and strong binding to the surface of B‐lineage leukaemia/lymphoma cells. Engagement of CD19 co‐receptor on B‐lineage ALL cells with CD19‐L perturbed the CD19‐associated signalling network, altering the expression levels of multiple genes directly involved in regulation of apoptosis, and triggered rapid apoptotic cell death in a CD19‐specific manner. The identification of human CD19‐L may lead to therapeutic innovation for B‐lineage ALL and other B‐lineage lymphoid malignancies as well as B‐cell lymphoproliferative states and systemic autoimmunity.

2011-03-25·Molecular vision

KH906, a recombinant human VEGF receptor fusion protein, is a new effective topical treatment for corneal neovascularization.

Article

作者: Zhong, Qi ; Pan, Jianying ; Huang, Juan ; Tang, Shibo ; Li, Tao ; Luo, Yan ; Hu, Andina ; Yang, Jin ; Li, Shiqing ; Yu, Honghua ; Ma, Wei ; Wu, Jianming

PURPOSEThe purpose of the current study was to investigate the effect of topical administration of KH906 on corneal neovascularization (NV).METHODSTo induce corneal neovascularization, chemical cauterization of the corneas of the right eyes of forty-eight New Zealand white rabbits was performed by touching the central cornea with an 8-mm-diameter NaOH-soaked Whatman filter paper for 60 s. On the next day after modeling, the rabbits were randomly and equally divided into six groups: PBS control group, 0.1% dexamethasone group, 10 mg/ml Avastin group, 5 mg/ml KH906 group, 10 mg/ml KH906 group, and 20 mg/ml KH906 group. The rabbits in the six groups received topical administration of 50 μl of the different solutions on the cornea four times per day for 14 days. Corneal neovascularization was analyzed by slit-lamp biomicroscopy 10 and 14 days after chemical cauterization. Corneal fluorescein staining was performed to evaluate the extent of corneal epithelial defect on the 7th, 10th, and 14th days. The VEGF level of the cornea was evaluated by ELISA assay.RESULTSOn the 10th and 14th days after chemical cauterization, the length of the longest new vessel and the areas of corneal neovascularization in all KH906-treated groups were significantly reduced compared to those of the PBS-treated group (p<0.05). The VEGF level of the cornea in all KH906-treated groups was significantly decreased compared to that of the PBS-treated group (p<0.05). Corneal fluorescein staining showed that KH906 had no effect on corneal epithelial healing.CONCLUSIONSTopical administration of KH906 significantly inhibited alkali burn-induced corneal neovascularization in rabbits. The new eye drops of KH906 may have a broad application for human corneal neovascularization in the near future.

2000-09-15·Applied Microbiology and Biotechnology3区 · 工程技术

Fed-batch production of recombinant human calcitonin precursor fusion protein using Staphylococcus carnosus as an expression-secretion system

3区 · 工程技术

Article

作者: R. Freudl ; M.-R. Kula ; D. Weuster-Botz ; W. Paul ; J. Thömmes ; S. Dilsen ; D. Tippe ; R. Takors ; C. Wandrey ; A. Sandgathe

A pH-auxostatic fed-batch process was developed for the secretory production of a fusion protein consisting of the pro-part of Staphylococcus hyicus lipase and two synthetic human calcitonin (hCT) precursor repeats under the control of a xylose-inducible promotor from Staphylococcus xylosus. Using glycerol as the energy source and pH-controlled addition of yeast extract resulted in the production of 2000 mg 1(-1) of the fusion protein (420 mg 1(-1) of the recombinant hCT precursor) within 14 h, reaching 45 g 1(-1) cell dry mass with Staphylococcus carnosus in a stirred-tank reactor. Product titer and space-time yield (30 mg calcitonin precursor 1(-1) h(-1)) were thus improved by a factor of 2, and 4.5, respectively, compared to Escherichia coli expression-secretion systems for the production of calcitonin precursors. Two hundred grams of the fusion protein was secreted by the recombinant S. carnosus on a 150-1 scale (scale-up factor of 50) with a minimum use of technical-grade yeast extract (40 mg fusion protein g(-1) yeast extract).

100 项与 F-637 相关的药物交易

登录后查看更多信息